Protracted stress-induced hypocortisolemia may account for the clinical and immune manifestations of Long COVID

[1]  H. Volk,et al.  Author Correction: A prospective observational study of post-COVID-19 chronic fatigue syndrome following the first pandemic wave in Germany and biomarkers associated with symptom severity , 2022, Nature Communications.

[2]  C. D. Dela Cruz,et al.  Distinguishing features of long COVID identified through immune profiling , 2022, Nature.

[3]  R. Shafer,et al.  Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) is common in post-acute sequelae of SARS-CoV-2 infection (PASC): Results from a post-COVID-19 multidisciplinary clinic. , 2022, medRxiv.

[4]  C. Brightling,et al.  Long COVID: which symptoms can be attributed to SARS-CoV-2 infection? , 2022, The Lancet.

[5]  J. Rosmalen,et al.  Persistence of somatic symptoms after COVID-19 in the Netherlands: an observational cohort study , 2022, The Lancet.

[6]  P. Sfikakis,et al.  Prevalence and patterns of anti-osteoporotic drug use based on 2019 real-world nationwide data in Greece , 2022, Archives of Osteoporosis.

[7]  F. Fostira,et al.  Management and Long-Term Follow-Up of Hyperparathyroidism in Multiple Endocrine Neoplasia Type 1: Single Center Experience , 2022, Journal of clinical medicine.

[8]  M. Merad,et al.  Pathological sequelae of long-haul COVID , 2022, Nature Immunology.

[9]  anonymous.  COVID is here to stay: countries must decide how to adapt , 2022, Nature.

[10]  Inyoul Y. Lee,et al.  Multiple early factors anticipate post-acute COVID-19 sequelae , 2022, Cell.

[11]  L. Wain,et al.  Clinical characteristics with inflammation profiling of Long-COVID and association with one-year recovery following hospitalisation in the UK: a prospective observational study , 2021, medRxiv.

[12]  G. Chrousos,et al.  Alterations in cortisol and interleukin-6 secretion in patients with COVID-19 suggestive of neuroendocrine-immune adaptations , 2021, Endocrine.

[13]  P. Sfikakis,et al.  Impaired adrenal cortex reserve in patients with rheumatic and musculoskeletal diseases who relapse upon tapering of low glucocorticoid dose. , 2021, Clinical and experimental rheumatology.

[14]  Michael Hittle,et al.  Assessment of the Frequency and Variety of Persistent Symptoms Among Patients With COVID-19 , 2021, The Journal of Emergency Medicine.

[15]  D. Mancini,et al.  Use of Cardiopulmonary Stress Testing for Patients With Unexplained Dyspnea Post–Coronavirus Disease , 2021, JACC: Heart Failure.

[16]  A. Aguzzi,et al.  COVID-19 targets human adrenal glands , 2021, The Lancet Diabetes & Endocrinology.

[17]  G. Chrousos,et al.  Adrenocortical dysfunction in rheumatoid arthritis: Α narrative review and future directions , 2021, European journal of clinical investigation.

[18]  S. Nanda,et al.  Secondary Adrenal Insufficiency and Growth Hormone Deficiency in Patients with Fibromyalgia , 2021, Journal of pain research.

[19]  Pei-Ning Wang,et al.  Salivary cortisol is associated with cognitive changes in patients with fibromyalgia , 2021, Scientific Reports.

[20]  M. Yavropoulou,et al.  Increased osteoclastogenesis in patients with vertebral fractures following discontinuation of denosumab treatment. , 2017, European journal of endocrinology.

[21]  E. Clayton.  Beyond myalgic encephalomyelitis/chronic fatigue syndrome: an IOM report on redefining an illness. , 2015, JAMA.

[22]  G. Chrousos,et al.  Adrenal insufficiency , 2014, The Lancet.

[23]  G. Chrousos,et al.  Post‐SARS sickness syndrome manifestations and endocrinopathy: how, why, and so what?* , 2005, Clinical endocrinology.

[24]  M. Leow,et al.  Hypocortisolism in survivors of severe acute respiratory syndrome (SARS) , 2005, Clinical endocrinology.

[25]  G. Chrousos,et al.  Endocrine withdrawal syndromes. , 2003, Endocrine reviews.

[26]  D. Papanicolaou,et al.  Acute glucocorticoid deficiency is associated with plasma elevations of interleukin-6: does the latter participate in the symptomatology of the steroid withdrawal syndrome and adrenal insufficiency? , 1996, The Journal of clinical endocrinology and metabolism.

[27]  S. Pillemer,et al.  Hypothalamic-pituitary-adrenal axis perturbations in patients with fibromyalgia. , 1994, Arthritis and rheumatism.

[28]  E. D. de Kloet,et al.  Altered reactivity of the hypothalamic-pituitary-adrenal axis in the primary fibromyalgia syndrome. , 1993, The Journal of rheumatology.

[29]  G. Chrousos,et al.  The concepts of stress and stress system disorders. Overview of physical and behavioral homeostasis. , 1992, JAMA.

[30]  M. Demitrack,et al.  Evidence for impaired activation of the hypothalamic-pituitary-adrenal axis in patients with chronic fatigue syndrome. , 1991, The Journal of clinical endocrinology and metabolism.